Scientists studied the effects of two different medications in animal models. Resiniferatoxin and capsazepine are known to impact TRPV1, an ion receptor channel that signals sharp, painful stimuli to the brain and triggers a pain response. These drugs block the activation of the TRPV1 receptor in different ways.
The researchers found that the chemical reaction after taking resiniferatoxin also negatively impacts the body’s reaction to bacterial infections by altering cytokine and chemokine expression, signaling molecules which are key to the natural immune response to bacteria.
Read the news release about resiniferatoxin.
Related Articles on Pain Management:
NeurogesX Reports $2.3M in Total Revenue for 4Q FY 2010
Kentucky AG Office Says County Governments Cannot Ban Pain Clinics
Opioid Pain Medications Drive “Epidemic” of Unintentional Drug Overdose Deaths
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.